Given that the use of HSP90 inhibitors may block pro-survival resistance mechanisms in AML blasts such as AKT overexpression, quantitation of AKT levels following ganetespib exposure was performed in a cohort of primary AML cells (n = 6) and results show a dose dependant loss of AKT expression (Fig. 3D). The gene discussed is AKT1; the disease is acute myeloid leukemia.